Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health TDM Coverage Policy Update | OpenPaye…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage for measurement of serum drug levels and anti‑drug antibodies for biologic therapies (primarily anti‑TNF agents, ustekinumab, vedolizumab, rituximab) with specific coverage decisions for inflammatory bowel disease versus other indications; applies to Oscar Health members and providers submitting reimbursement claims.

    Policy Summary
    PayerOscar Health
    PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionFor individuals with IBD, order drug and/or antibody concentration testing at the end of induction and at least once during maintenance; testing may be performed every two weeks when indicated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Every 2 weeksIBD testing frequency allowed
    10Drugs listed as not meeting criteria (non-IBD)
    >2 µg/mLInfliximab trough threshold assoc. with remission
    80145–80299, 82397, 0514U–0515U

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Procedure codes listed
    2026-06-16Policy governance approval

    Coverage Criteria for Therapeutic Drug and Anti-Drug Antibody Monitoring

    IBD therapeutic drug/antibody monitoring

    Covered when the stated conditions are met

    IBD - Covered: For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti-TNF therapies, vedolizumab therapy, or ustekinumab therapy MEETS CRITERIA.once every two weeks

    Applies to anti-TNF agents, vedolizumab, ustekinumab

    Non-IBD and other situations

    Not covered when the following conditions are present

    Non-IBD indications - Not covered: For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti-TNF therapies DOES NOT MEET CRITERIA.N/A

    Examples listed in policy: spondyloarthritis, RA, psoriatic arthritis, psoriasis

    Other situations/drugs - Not covered: For all other situations not addressed above, measurement of serum drug levels and/or antibodies to the following drugs DOES NOT MEET CRITERIA: adalimumab; certolizumab; etanercept; golimumab; infliximab; infliximab-dyyb; infliximab-abda; rituximab; ustekinumab; vedolizumab.N/A

    List is explicit in policy; applies when situation not otherwise addressed

    Consensus-based appropriate scenarios for TDM

    Appropriate to order drug/antibody concentration testing in the following distinct scenarios as supported by consensus statements and guidelines:

    Anti-TNF responders at end of induction: Order drug/antibody concentration testing in responders at the end of induction for all anti-TNFs.

    Consensus 92% (12/13)

    Anti-TNF maintenance monitoring: Order drug/antibody concentration testing at least once during maintenance for patients on anti-TNFs.

    Consensus 100% (13/13)

    Primary non-responders at end of induction: Order testing of anti-TNF drug/antibody concentrations at the end of induction in primary non-responders.

    Consensus 100% (13/13)

    Confirmed secondary loss of response: Order testing for anti-TNFs in patients with confirmed secondary loss of response.

    TDM Coverage Criteria (consensus statements)

    Consensus-based indications and principles for performing TDM (reactive and proactive) in IBD and related immune-mediated diseases

    Reactive TDM indications: Reactive TDM should be performed in patients with confirmed primary non-response or confirmed secondary loss of response to anti-TNF therapy and in patients with primary or secondary non-response to vedolizumab or ustekinumab prior to switching therapy; TDM (drug concentration and antibodies) should be performed following a drug holiday prior to re-dosing infliximab.
    Proactive TDM recommendations: Proactive TDM should be performed post-induction and at least once during maintenance for patients treated with anti-TNF therapy; proactive TDM is most important in more severely active patients and those with higher drug clearance; proactive TDM is recommended both prior to and after infliximab de-escalation.
    Assay and assay-use principles: All commercially available assays are appropriate for TDM but specific cut-offs for high-titer antibodies are not established for most assays beyond HMSA; patients should be followed with the same assay when possible until cross-validation and standardization occur.

    Testing for anti-TNF therapies outside of inflammatory bowel disease (IBD) is not supported by this policy. Drug and/or antibody concentration testing for anti‑TNF agents DOES NOT MEET CRITERIA for conditions such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis. Documented clinical context that indicates IBD is required to align with coverage criteria and reduce the risk of claim denial.

    For IBD indications the policy explicitly allows testing (see IBD coverage criteria), but when ordering TDM for non‑IBD immune‑mediated diseases clinicians should be aware that evidence and guideline guidance differ by specialty and that testing for these other indications may not be covered.

    Some guideline bodies have cautioned against routine adoption of ELISA kits for TNF inhibitor monitoring outside research contexts. The National Institute for Health and Clinical Excellence (NICE, 2016) stated that ELISA kits “show promise” but that there is currently insufficient evidence to recommend their routine adoption, and recommended their use primarily within research or data‑collection settings.

    Similarly, guideline technical reviews and society statements note that proactive routine monitoring in quiescent IBD lacks consistent evidence of benefit and should not be universally applied; proactive testing strategies should be aligned with published guideline recommendations and study contexts.

    The policy recognizes important evidence gaps for proactive therapeutic drug monitoring (TDM) of biologics other than anti‑TNF agents. Consensus statements agree that more data are needed to support routine proactive TDM for non‑anti‑TNF biologics, and current recommendations focus on selective use (for example, reactive TDM or post‑induction checks) rather than universal proactive schedules.

    For vedolizumab and ustekinumab the policy notes emerging associations between drug levels and outcomes but explicitly states that these data are insufficient to define specific induction or maintenance target concentrations beyond confirming detectable drug.

    The reference and publication‑history sections of the policy list supporting literature and guideline sources but do not state explicit coverage exclusions beyond those already included in the policy language. No separate or additional exclusionary statements are present in the referenced publication‑history sections.

    Providers should rely on the policy’s Coverage Criteria and Not Medically Necessary sections for the operative coverage stance rather than expecting additional exclusions to appear in the reference lists.

    Measurement of serum drug levels and/or anti‑drug antibodies for the drugs listed in the policy is considered not medically necessary when used in situations not specifically addressed by the coverage criteria. The policy lists specific agents (including adalimumab, certolizumab, etanercept, golimumab, infliximab and its biosimilars, rituximab, ustekinumab, and vedolizumab) and states that testing for these agents DOES NOT MEET CRITERIA outside of the defined IBD contexts or other expressly permitted scenarios.

    When clinical indications are not explicitly covered (for example, non‑IBD presentations or unspecified contexts), providers should document the clinical justification and recognize that such testing may be denied as not medically necessary.

    Routine proactive TDM for all unselected patients in clinical remission (quiescent IBD) is of uncertain benefit and is not uniformly recommended. Some guideline statements specifically advise against universal proactive monitoring in quiescent ulcerative colitis and emphasize targeted TDM for patients with active disease, at high risk of relapse, or when considering de‑escalation.

    The policy aligns with guideline recommendations by supporting proactive TDM post‑induction and at least once during maintenance for anti‑TNF therapies, particularly in higher‑risk or more severely active patients, but it does not endorse routine, indiscriminate proactive testing in all patients in remission.

    For vedolizumab and ustekinumab there is currently insufficient evidence to specify target induction and maintenance trough concentrations. Consensus language in the policy indicates that while detectable drug levels are generally required, specific numeric targets for induction and maintenance have not been established for these agents and therefore cannot be used as firm coverage thresholds.

    As a result, testing for these agents may be used to confirm drug exposure or to aid clinical decision‑making in non‑routine situations, but the absence of validated target ranges limits the use of proactive TDM‑based dosing algorithms for vedolizumab and ustekinumab.

    Although the policy cites an extensive evidence base and lists multiple references, the referenced sections do not contain explicit statements labeling particular tests or scenarios as categorically “not medically necessary” beyond the policy’s own Not Medically Necessary language. No additional explicit 'not medically necessary' statements are present in the publication history or reference listings.

    Coverage determinations should therefore be made using the policy’s coverage and exclusion sections supported by the referenced literature, rather than expecting standalone NNM statements in the bibliography.

    There are unaddressed situations in which measurement of serum drug levels and/or anti‑drug antibodies may be requested (for example, indications outside IBD, rare clinical scenarios, or agents where the policy provides limited guidance). In such cases the policy treats testing as not meeting criteria unless a covered scenario applies; clinicians should provide clear documentation of the clinical rationale when ordering tests that are not explicitly addressed.

    When considering testing in unaddressed situations, providers should reference guidance cited in the policy (for example, NICE and ACG statements) and be prepared to justify testing as part of research, data collection, or a specific clinical management plan consistent with the available evidence.

    Procedure Codes, Thresholds, and Test Identifiers

    Procedure and proprietary assay codes referencedmixed
    80145Adalimumab
    80230Infliximab
    80280Vedolizumab
    80299Quantitation of therapeutic drug, not elsewhere specified
    82397Chemiluminescent assay
    0514UImmunoassay for quantitative determination of adalimumab (Procise ADL™) — proprietary assay (ProciseDx Inc.)
    0515UImmunoassay for quantitative determination of infliximab (Procise IFXT™) — proprietary assay (ProciseDx Inc.)
    Infliximab trough concentration (TC)
    Maintenance trough associated with mucosal healing (UC)Infliximab trough concentration (TC) ≥ 2.1 µg/mL is associated with mucosal healing in ulcerative colitis.
    Association with remission probabilityDuring maintenance, an infliximab trough level > 2 µg/mL is associated with a greater probability of clinical remission and mucosal healing.
    Typical mean trough in studiesMedian trough infliximab reported in a cohort was 3.7 µg/mL; ~23% of samples were ≤ 1 µg/mL.
    Targeted IFX trough ranges used in a proactive regimen
    Target range for Crohn's disease (CD)Infliximab trough target: 3–7 µg/mL in proactive regimens for CD.
    Target range for Ulcerative colitis (UC)

    Provider Responsibilities, Prior Authorization, and Management Actions

    Prior Authorization

    Coverage for IBD testing

    For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing for anti‑TNF agents, vedolizumab, or ustekinumab meets criteria when performed at the frequencies cited in the policy (examples include testing at the end of induction and at least once during maintenance; policy also allows testing “once every two weeks” in IBD when the stated conditions are met).

    • Examples of endorsed timepoints: end of induction and at least once during maintenance for anti‑TNFs (consensus statements).
    • Policy language: “For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti‑TNF therapies, vedolizumab therapy, or ustekinumab therapy MEETS CRITERIA.”
    Prior Authorization

    Align prior authorization to guideline indications

    Prior authorization determinations and requests should align with guideline‑endorsed indications — principally reactive TDM for active IBD and consideration of testing at end of induction and at least once during maintenance for anti‑TNF agents as described by consensus and GI society guidance.

    Background and Rationale

    Anti-drug antibodies can reduce biologic efficacy and promote adverse immune effects, which is the clinical rationale for targeted monitoring. The policy frames therapeutic drug monitoring (measurement of trough drug levels and anti-drug antibodies) as a tool to manage primary nonresponse, confirmed secondary loss of response, and to inform decisions about dose optimization or switching therapy—particularly for anti-TNF agents where the evidence and guidance are strongest.

    Definitions and Key Terms

    Anti-tumor necrosis factor
    DefinitionAnti-tumor necrosis factor (anti-TNF): biologic therapies targeting tumor necrosis factor used to treat immune-mediated inflammatory diseases.
    ExamplesIncludes agents such as infliximab, adalimumab, certolizumab, golimumab and etanercept as listed in the policy terminology and indications.
    Clinical relevanceAnti-TNF agents are the primary biologics discussed for TDM in IBD where drug and antibody concentration testing meets criteria.
    Therapeutic drug monitoring (TDM)
    DefinitionTherapeutic drug monitoring (TDM): measurement of serum drug trough levels and anti-drug antibodies to guide management of biologic therapies.
    PurposeUsed to manage loss of response, guide dose adjustment, or inform switching of biologic agents.
    Policy Summary
    PayerOscar Health
    PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionFor individuals with IBD, order drug and/or antibody concentration testing at the end of induction and at least once during maintenance; testing may be performed every two weeks when indicated.
    SourceLink
    On This Page
    Coverage Criteria for Therapeutic Drug and Anti-Drug Antibody MonitoringProcedure Codes, Thresholds, and Test IdentifiersProvider Responsibilities, Prior Authorization, and Management ActionsBackground and RationaleDefinitions and Key Terms

    Consensus 100% (13/13)

    Vedolizumab/ustekinumab non-responders and secondary loss: Order drug/antibody concentration testing for vedolizumab and ustekinumab in non-responders at end of induction and in patients with confirmed secondary loss of response; routine proactive thresholds are not established for these agents.

    Mixed consensus; detectable drug generally required but specific thresholds insufficient

    Immunogenicity management: Anti-drug antibodies are more clinically relevant when trough drug concentrations are undetectable; low-titer antibodies (<10 U/mL by HMSA for infliximab) can sometimes be overcome by treatment optimization; high-titer anti-drug antibodies prompting secondary loss of response should lead to switching therapy rather than dose escalation; when switching within class after antibody-mediated loss, add an immunomodulator to the new anti-TNF therapy.
    Infliximab trough target: 5–10 µg/mL in proactive regimens for UC.
    Proactive measurement scheduleMeasured before the fourth infusion and subsequently every two infusions in the described proactive regimen.
    Low infliximab concentration flag
    Low infliximab concentration definitionInfliximab trough concentration ≤ 1 µg/mL is considered low.
    Clinical implicationApproximately 85% of samples with positive anti-infliximab antibodies had infliximab ≤ 1 µg/mL, supporting antibody measurement when IFX ≤ 1 µg/mL.
    Associated biomarker differenceSerum C-reactive protein was significantly higher when infliximab ≤ 1 µg/mL versus >1 µg/mL.
    Biologic trough concentration thresholds (selected)
    Infliximab post-induction/maintenancePost-induction (week 14) minimal trough >3 µg/mL; concentrations >7 µg/mL associated with increased likelihood of mucosal healing; maintenance minimal trough >3 µg/mL for patients in remission.
    Adalimumab thresholdsWeek 4 minimal concentration ≥5 µg/mL; >7 µg/mL associated with mucosal healing; maintenance trough >5 µg/mL for remission.
    Other biologics (selected)Certolizumab: week 6 >32 µg/mL, maintenance 15 µg/mL; Golimumab: week 6 ≥2.5 µg/mL, maintenance >1 µg/mL.
    Infliximab/Adalimumab concentration for withholding discontinuation
    Suggested threshold before discontinuationFor secondary loss of response, consider withholding discontinuation of infliximab or adalimumab until drug concentrations reach at least 10–15 µg/mL.
    Context of useRecommendation arises in reactive TDM for secondary loss of response to anti-TNF agents.
    Panel agreementStatement on 10–15 µg/mL threshold was supported in the consensus voting tables.
    • AGA suggests reactive TDM in adults with active IBD treated with anti‑TNF agents; routine proactive monitoring in quiescent IBD is not generally recommended.
    • ACG/consensus statements recommend testing at end of induction and at least once during maintenance for anti‑TNFs.
    Billing Rule

    Procedure codes for TDM

    Use the procedure and proprietary assay codes listed in the policy when submitting claims or prior authorization requests for immunopharmacologic monitoring.

    • CPT/HCPCS listed: 80145, 80230, 80280, 80299, 82397.
    • Proprietary assay codes listed: 0514U (Procise ADL™), 0515U (Procise IFXT™).
    Note

    Prior authorization

    The publication‑history and reference sections do not specify any additional prior authorization requirements applicable to this policy.

    • Publication history records governance approval on 06/16/2026.
    Step Therapy

    Clinical approach to therapy adjustment

    Typical clinical practice is to adjust or switch bDMARDs only when clinical evidence shows remission or low disease activity is not achieved or maintained; concomitant immunomodulators (e.g., methotrexate or thiopurines) may be used to reduce immunogenicity.

    • Policy: adjust or switch bDMARDs when there is clinical evidence that remission or low disease activity is not achieved or maintained.
    • ACG recommends considering combination therapy with immunomodulators in patients with prior anti‑TNF antibodies to reduce immunogenicity.
    Step Therapy

    Therapy change recommended for high‑titer antibodies

    When TDM demonstrates absent drug with high‑titer anti‑drug antibodies (especially for infliximab), switching therapy is recommended rather than dose escalation; low‑level antibodies may be managed with treatment optimization.

    • High‑titer antibodies prompting secondary loss of response should lead to switching therapy rather than dose escalation.
    • Low‑titer antibodies (e.g., <10 U/mL by HMSA for infliximab) can potentially be overcome by dose optimization or adding an immunomodulator.
    Step Therapy

    Management after antibody‑mediated loss of response

    For secondary loss of response to an anti‑TNF caused by high‑titer anti‑drug antibodies, do not dose‑escalate — instead change to an alternative therapy; if switching within class after antibody‑mediated loss, add an immunomodulator to the subsequent anti‑TNF regimen.

    • Policy statement: patients with secondary loss of response due to high‑titer antibodies should be switched (within‑class or out‑of‑class).
    • When switching within class after antibody‑mediated loss, add an immunomodulator to the new anti‑TNF therapy.
    Step Therapy

    Step therapy considerations

    The literature compares proactive versus reactive TDM and standard therapy, but the policy does not establish explicit payer step‑therapy rules — payers should not infer additional mandatory step requirements beyond the published guidance.

    • Referenced studies evaluate proactive vs reactive TDM (e.g., cost‑effectiveness and outcomes) but no explicit payer step‑therapy mandates are stated in the policy.
    Billing Rule

    Billing and documentation responsibility

    Providers are responsible for submitting accurate documentation and using appropriate industry‑standard coding when billing for TDM services; failure to follow coding/billing guidelines may result in denial or recoupment.

    • Policy requires coding per standard sources (CPT®, HCPCS, ICD‑10, CMS guidance).
    • Claims may be denied or recouped if appropriate coding/billing guidelines or current reimbursement policies are not followed.
    Documentation Required

    Document disease activity and reason for testing

    Document the clinical context when ordering TDM — specify disease activity (active vs quiescent), whether testing is for primary nonresponse, secondary loss of response, or post‑induction assessment to align with guideline recommendations.

    • AGA/ACG and consensus statements endorse reactive testing for active disease and testing at end of induction; documentation should state the reason for testing.
    • Include status (e.g., primary nonresponse, secondary loss of response, post‑induction) in the medical record and submission materials.
    Documentation Required

    Laboratory validation

    Laboratory‑developed tests (LDTs) used for TDM are regulated under CLIA as high‑complexity tests; laboratories must validate and perform these assays in‑house per CMS/CLIA requirements.

    • LDTs are not FDA‑cleared/approved for clinical use and must be validated and performed in‑house; regulated by CMS under CLIA '88 as high‑complexity tests.
    Denial Risk

    Limited evidence may lead to non‑coverage

    Some proactive TDM uses and testing for indications other than IBD (e.g., RA, psoriatic arthritis, spondyloarthritis, psoriasis) are less supported by the policy and may not meet criteria — ordering TDM outside IBD risks denial.

    • Policy: testing for conditions other than IBD does not meet criteria (examples listed include spondyloarthritis, RA, psoriatic arthritis, psoriasis).
    • Guidance: AGA/ACG note limited support for routine proactive monitoring in quiescent IBD and variable evidence for non‑IBD indications.
    Denial Risk

    Conflict with government policy

    If there is any conflict between this policy and applicable government coverage (LCDs/NCDs or state Medicaid rules), follow the government policy — failure to do so may result in denial or use of the government policy to adjudicate coverage.

    • Policy disclaimer: government policy (LCD/NCD/state) supersedes this policy when conflicts exist; providers should check applicable Medicare/Medicaid guidance.
    Denial Risk

    Claim denial and recoupment risk

    Claims for TDM services may be denied or recouped if appropriate coding, billing, or current reimbursement policies are not followed; ensure claims match documented medical necessity and selected procedure codes.

    • Policy warning: we may deny the claim and/or recoup payment if coding/billing guidelines or reimbursement policies are not followed.
    • Accurate documentation and use of listed CPT/HCPCS/proprietary codes support proper claim adjudication.
    Note

    Publication history and governance

    Publication history documents governance approval on 06/16/2026; no additional procedural documentation requirements are specified in the publication‑history section.

    • Publication History: Original Documentation; Governance Approved 06/16/2026.
    Note
    Note
    Assay considerationsVarious commercially available assays are appropriate for TDM, but inter-assay comparability varies by drug; follow-up with the same assay is recommended when possible.
    Proactive TDM
    DefinitionProactive TDM: scheduled measurement of serum drug levels and anti-drug antibodies after induction and periodically during maintenance regardless of clinical worsening to optimize dosing and prevent loss of response.
    Consensus recommendationFor anti-TNF therapies, proactive TDM is appropriate after induction and at least once during maintenance; not routinely established for non-anti-TNF biologics.
    Typical timing exampleExamples include post-induction measurement (e.g., week 14 for infliximab) and periodic checks during maintenance; proactive regimens in studies measured before the fourth infusion and every two infusions thereafter.
    Reactive TDM
    DefinitionReactive TDM: measurement of serum drug levels and anti-drug antibodies in response to active disease, primary nonresponse, or confirmed secondary loss of response to guide treatment decisions.
    When to performReactive TDM should be performed in patients with confirmed primary non-response or secondary loss of response to anti-TNF therapy and prior to switching therapy for vedolizumab or ustekinumab non-responders.
    Clinical utilityReactive TDM has been shown to be cost-effective compared with empiric anti-TNF optimization in some studies and is recommended by guideline panels for active IBD cases.
    High-titer anti-drug antibodies
    DefinitionHigh-titer anti-drug antibodies: antibody levels to biologic agents that are sufficiently high to be clinically relevant and commonly associated with secondary loss of response.
    Management implicationHigh-titer antibodies with undetectable trough drug concentrations warrant switching therapy rather than dose escalation; when switching within class, add an immunomodulator to the subsequent anti-TNF.
    Assay cutoffsSpecific cutoffs for high-titer anti-infliximab antibodies are provided for some assays (e.g., ANSER: 10 U/mL; RIDAscreen and InformTx/Lisa Tracker: 200 ng/mL), but are not established for most assays.
    Low-titer antibodies (HMSA)
    HMSA low-titer definitionFor the homogeneous mobility shift assay (HMSA), low-titer anti-infliximab antibodies can be defined as <10 U/mL.
    Management implicationLow-titer antibodies may be overcome by treatment optimization such as dose escalation, interval shortening, or adding an immunomodulator.
    Consensus supportPanel statements indicate low-titer antibodies can sometimes be managed without switching therapy.
    Therapeutic drug monitoring (TDM) — summary
    Summary definitionTherapeutic drug monitoring (TDM): measurement of serum trough drug concentrations and anti-drug antibodies for biologic agents to guide clinical management in IBD and other immune-mediated diseases.
    Primary usesUsed to diagnose causes of loss of response, inform dose optimization, and guide switching between biologic agents.
    Evidence baseGuidelines and consensus statements (AGA, ACG, and expert panels) support reactive TDM for active disease and recommend proactive TDM after induction and at least once during maintenance for anti-TNF therapies.